GlobeNewswire by notified

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Share

Company Announcement

COPENHAGEN, Denmark; November 23, 2022Genmab A/S (Nasdaq:GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons.

The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons.

About Genmab
Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer. For more than 20 years, Genmab’s vision to transform cancer treatment has driven its passionate, innovative and collaborative teams to invent next-generation antibody technology platforms and leverage translational research and data sciences, fueling multiple differentiated cancer treatments that make an impact on people’s lives. To develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. Genmab’s proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.

Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on Twitter.com/Genmab.

Contact:
Marisol Peron, Senior Vice President, Communications and Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com

The Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.comand the risk factors included in Genmab’s most recent Annual Report on Form 20-Fand other filingswith the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov.Genmab does not undertake any obligation to update or revise forward looking statements in the Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®;HexaBody in combination withthe HexaBody logo®; DuoHexaBody® and HexElect®.



CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Ress Life Investments A/S publishes annual report7.12.2022 18:09:31 CET | Press release

Ress Life Investments A/S Corporate Announcement no. 44/2022 Annual Report 2021/22 http://www.resslifeinvestments.com/ CorporateAnnouncementno.44/2022:AnnualReport1October2021–30 September2022 Copenhagen, 7 December 2022 The Board of Directors and Management have today discussed and approved the Annual Report of Ress Life Investments A/S for the period 1 October 2021 – 30 September 2022. Key results and highlights: Ress Life Investments A/S realised a net profit before and after tax of USD 34,895,871 for the period 1 October 2021 – 30 September 2022. Net profit for the period corresponds to a net return on equity of 10.5% and an increase in net asset value of USD 229 per share. The increase in profit mainly relates to pay-outs of policies offset by administrative expenses and staff costs. The fair value of the Group’s investment assets increased from USD 255,262,257 at 30 September 2021 to USD 303,228,365 at 30 September 2022. The Group’s investments in treasury bills increased from US

PRESS RELEASE NACON: Ishtar Games, NACON’s indie label, announces new publishing line-up:7.12.2022 18:00:00 CET | Press release

Ishtar Games, NACON’s indie label, announces new publishing line-up After 17 years of developing games, Ishtar Games now also provides dedicated and passionate publishing support to its first group of studio partners. Lille, France, December 7th, 2022 — NACON is pleased to announce that its studio and indie-publishing label, Ishtar Games, developer behind Dead in Vinland, The Last Spell, reveals today the first games they will publish: Worlds of Aria (Ludogram Games), Spirited Thief (Koi Snowman Games), and their own developed game Lakeburg Legacies, all releasing in 2023. Take a look at the first line-up reveal trailer: https://youtu.be/7OpVbH7Rq-o "We are super excited to initiate our indie publishing label’s journey with Koi Snowman and Ludogram," Ishtar Games CEO and Creative Director Matthieu Richez said. "They have brought to us not only excellent games, but also great human beings to work with. I am convinced that this collaboration will bear fruit for all parties involved, whic

Ilkka Oyj – Acquisition of own shares on 7 December 20227.12.2022 18:00:00 CET | Press release

ILKKA OYJ, STOCK EXCHANGE RELEASE, 7 December 2022 at 19:00 EET IlkkaOyj – Acquisition of own shares on 7 December 2022 At Nasdaq Helsinki Ltd: Date7 December 2022Exchange transactionBuyShare trading codeILKKA2Amount, shares 1,350Average price/share, EUR3.6969Total cost, EUR4,990.82 The company holds a total of 2,917 of its own shares (ILKKA2) including the shares acquired on 7 December 2022. Detailed information concerning the acquisition is attached to this stock exchange release. On behalf of Ilkka Oyj DANSKE BANK A/S, FINLAND BRANCH Jonathan Nyberg Antti Väliaho Additional information Olli Pirhonen, CEO, Ilkka Oyj, tel. +358 40 766 5418 www.ilkka.com Attachment Ilkka buyback 7.12.2022

Rovio Entertainment Corporation: Repurchase of own shares on 7 December 20227.12.2022 17:45:00 CET | Press release

Rovio Entertainment Oyj STOCK EXCHANGE RELEASE 7.12.2022 at 18.45 EETRovio Entertainment Corporation - Repurchase of own shares on 7.12.2022Rovio Entertainment CorporationIn the Nasdaq HelsinkiDate7.12.2022Exchange transactionBUYShare trading codeROVIOAmount, shares32063Average price/share, EUR6,023788Total cost, EUR193140,71Rovio now holds a total of 6 548 427 shares including the shares repurchased on 7.12.2022On behalf of Rovio Entertainment CorporationOP Corporate Bank PLC Further information: Timo Rahkonen, VP Investor Relations & Corporate Strategy +358 40 730 3442 RovioIR@rovio.com Distribution: Nasdaq Helsinki Ltd Key media www.rovio.com About Rovio: Rovio Entertainment Corporation is a global mobile-first games company that creates, develops and publishes mobile games, which have been downloaded over 5 billion times. Rovio is best known for the global Angry Birds brand, which started as a popular mobile game in 2009, and has since evolved from games to various entertainment, a

Park Street A/S – New share buyback program7.12.2022 17:34:07 CET | Press release

Park Street A/S – New share buyback program Transactions during 01 December 2022 – 07 December 2022 On 14th September 2022, Park Street A/S announced a share buy-back programme, as described in Company Announcement dated 14-09-2022. The programme is carried out in compliance with the provisions of Regulation No 596/2014 of the European Parliament and of the Council on market abuse (the Market Abuse Regulation – MAR) and delegated legislation under MAR; except for the limitation of implementing the authorized buy-back of the Company’s shares within the 25% daily trading volume, due to the low levels of market liquidity in the Company’s shares. According to the programme, Park Street A/S will repurchase Class A and Class B shares for up to DKK 50 million. The programme is taking place during the period from 06 September 2022 – 30 December 2022. The following transactions were made under the share buy-back programme during 01 December 2022 – 07 December 2022: Number of shares boughtAverag